Skip to main content

Table 1 Patients and transplant characteristics

From: Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

Characteristics HID MSD p
No. of patients 119 132
Median age, years (range) 28 (14–54) 33 (16–56) .127
Sex, no. (%)    .448
 Male/female 65 (54.6)/54 (45.4) 65 (49.2)/67 (50.8)  
Underlying diseases, (%)    .731
 AML 54 (45.4) 57 (43.2)  
 ALL 55 (46.2) 60 (45.4)  
 ALAL 10 (8.4) 15 (11.4)  
Disease stage at transplants, (%)    .447
 Primary induction failure 58 (48.7) 57 (43.2)  
 Relapse refractory 61 (51.3) 75 (56.8)  
WBC count at diagnosis, n (%)    .615
 ≥ 30,000 per mm3 57 (47.9) 59 (44.7)  
 < 30,000 per mm3 62 (52.1) 73 (55.3)  
Median BM blasts before conditioning (range) 33% (7.0–96.0%) 31% (8.0–98.0%) .602
Genetics, (%)    .527
 Poor 65 (54.6) 66 (50.0)  
 Intermediate 34 (28.6) 45 (34.1)  
 Favorable 5 (4.2) 8 (6.1)  
 Unknown 15 (12.6) 13 (9.8)  
Graft no. (%)    -
 BM + PBSC 119 (100) 3 (2.3)  
 PBSC 0 (0) 129 (97.7)  
Median MNCs, 108/kg (range) 7.36 (3.76–12.80) 7.80 (3.52–13.16) .136
MedianCD34 + count, 106/kg (range) 5.65 (1.15–15.16) 5.41 (0.98–16.46) .471
Follow-up time in survivors from transplant, median (range), mouth 43.4 (20.5–71.5) 41.6 (18.2–72.7) .814
  1. AML acute myelogenous leukemia, ALL acute lymphoblastic leukemia, ALAL acute leukemia of ambiguous lineage, MNC mononuclear cell, PBSC peripheral blood stem cell, BM bone marrow